NS Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

Continue Learn More X

Home » News » Company News » Castle Biosciences Announces Commercial Launch of DecisionDx DiffDx-Melanoma » medic-563425_640

Castle Biosciences Announces Commercial Launch of DecisionDx DiffDx-Melanoma

NS Medical Devices is using cookies

Castle Biosciences Announces Commercial Launch of DecisionDx DiffDx-Melanoma. (Credit: Darko Stojanovic from Pixabay.)

Related Article

Four major advances made in external radiotherapy for treating cancer

RECOMMENDED COMPANIES

MOST READ

Four major advances made in external radiotherapy for treating cancer

Vaxess timeline: The US biotech firm racing to bring its Covid-19 vaccine patch to clinical trials

Nine questions on electric manufacturing with Watlow chief system designer Andy Selvy

Top five medical device companies based in California by market cap

Bioengineered hybrid muscle fibre could be used to regenerate damaged muscle tissue

Recommended Whitepaper